News
ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b
September 14, 2021
Fast Track designation for the treatment of recurrent and metastatic HPV16-positive oropharyngeal cancer to improve survival an...
Read more
ORCA Therapeutics B.V. to Start Repeat-Dosing in Phase 1/2a Study of ORCA-010 in TreatmentNaïve Prostate Cancer Patients.
September 07, 2021
ORCA Therapeutics B.V. is pleased to announce the successful completion of the single-dose escalation cohorts of the Phase I/II...
Read more
Stepping to the Exit - Publication in Nature Biotechnology
August 27, 2021
Building a business. Stepping to the exit.
Read more
A Microfluidic 3D Endothelium-on-a-Chip Model to Study Transendothelial Migration of T Cells in Health and Disease
August 02, 2021
Scientists from MIMETAS and Merck introduce an assay to study 3D T cell dynamics under flow and in real-time using a high-throu...
Read more
ISA, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline
July 20, 2021
Grant accelerates clinical development of immunotherapy to treat chronic hepatitis B virus infection
Read more
ISA Pharmaceuticals announces successful closing of EUR 26 million funding round
July 13, 2021
The proceeds of this round will be used to advance the lead product ISA101b towards first marketing authorization as well as to...
Read more
MIMETAS and Roche enter into a collaboration to develop human disease models for drug development
July 06, 2021
- Risk-sharing alliance on tailor-made phenotypic models for IBD and HBV
- Upfront payment and milestone payments for MIMETAS...
Read more
Sapreme will present data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing compound SPT001 to enable superior targeted delivery of oligonucleotides.
June 10, 2021
Sapreme will present data at the RNAi-Based Therapeutics Summit, demonstrating the potential of its Endosomal Escape Enhancing...
Read more
MIMETAS wins Deshima award for Dutch-Japanese business relations
June 07, 2021
MIMETAS wins Deshima award for Dutch-Japanese business relations.
Read more
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
June 04, 2021
- 61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data...
Read more
Macrophage Pharma Appoints Dr Venkat Reddy as Chief Executive Officer
June 01, 2021
Macrophage Pharma Limited ('MPL') announced today that its Chief Scientific Officer (CSO), Dr Venkat Reddy PhD, has been appoin...
Read more
MIMETAS Opens Phenotypic Screening Center
May 27, 2021
Largest reported organ-on-a-chip screen ever performed on a 3D angiogenesis assay
Read more
ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines
May 04, 2021
The Nature Reviews Cancer paper summarizes key insights gleaned from previous successful and non-successful therapeutic vaccine...
Read more
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid Tumors
May 03, 2021
First patient has been treated in its phase 1/2 dose escalation and expansion trial evaluating MCLA-129 for the treatment of pa...
Read more
ISA has relocated to brand new Biopartner 5 building
May 03, 2021
ISA has relocated to brand new Biopartner 5 building
Read more
Modra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical Development
April 27, 2021
Modra Pharmaceuticals Appoints Two New Supervisory Board Members
Read more
InteRNA Technologies Publishes Preclinical Data from Investigational microRNA INT-1B3 Program in Molecular Therapy - Nucleic Acids and Oncotarget
March 24, 2021
Results further support the potential of lead candidate, INT-1B3, as novel option for
therapeutic intervention in oncology
Read more
InteRNA Technologies Awarded € 2.7M Clinical Innovation Credit from Dutch Government
March 11, 2021
This award will support the clinical validation of the Company's lead candidate, INT-1B3, for the treatment of solid tumors.
Read more
ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patients. Consistent Efficacy Data from First Cohort and Start New Indication. Additional funding secured.
March 05, 2021
ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patie...
Read more
ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy
March 03, 2021
ISA106's promising results in preclinical tests warrant fast entry into human studies to address the need for effective COVID-1...
Read more
